ملخص البحث :
Erythroferrone (ERFE) is a glycoprotein hormone produced by erythroblasts in
response to erythropoietic activity by stimulation of erythropoietin that acts directly on the
liver to inhibit production of hepcidin, lead to increases iron delivery for intensified activity
of erythropoietic. Beta thalassemia are inherited disorders characterized by reduced or absent
synthesis of beta globin chains in the hemoglobin (Hb) molecule1 The pathophysiology has
been recognized by anemia and iron overload continually with resultant of frequented blood
transfusions. We intend to investigate serum ERFE level and their associations with each
other. Beta Thalassemia (BT) patients, who were inspected at thalassemia center in
ALzahra`a hospital teaching period transfusions blood (PTB) for each (14-30 day). Seventy
patients were aged about (11-28 year) and 20 subjects healthy as control group, who matched
were included in the study. Results. Serum ERFE levels were significantly higher in BT
patients compared to control groups. There were significantly (p<0.05) differences in these
biomarker between (BTM and BTI), (splenectomy and non splenectomy) groups. a negative
correlation between ERFE levels with HB, PCV, MCV, MCH, Iron, and Ferritin while it was
a not significant correlated with MCHC and PTB. High level of ERFE as new biomarker in
patients with BTM and BTI is associated with mild or severe anemia and iron overload
especially in patients with splenectomy.
-
سنة النشر : 2019
-
تصنيف البحث : scopus
- تحميل